WHO recommends GenoType MTBDRsl VER 2.0
WHO recommends GenoType MTBDRsl as first and only rapid test for detection of additional resistance in MDR-TB patients as well as XDR-TB. The test system is recommended for patients with confirmed rifampicin-resistant TB or MDR-TB as the initial test to detect resistance to fluoroquinolones and the second-line injectable drugs, instead of phenotypic culture-based drug-susceptibility testing (DST).
Thus, step-wise diagnostics for MDR- and XDR-TB with GenoType MTBDRplus VER 2.0 and GenoType MTBDRsl VER 2.0 is possible!
Click on the picture for further information about the Recommendation
Click here for WHO webpage
Clicke here for further information about GenoType MTBDRsl VER 2.0